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FibrosisThe major gap junction protein expressed in the heart, connexin43 (Cx43), is highly remodeled in the
diseased heart. Usually, Cx43 is down-regulated and heterogeneously redistributed to the lateral sides of
cardiomyocytes. Reverse remodeling of the impaired Cx43 expression could restore normal cardiac function
and normalize electrical stability. In this review, the reduced and heterogeneous Cx43 expression in the heart
will be addressed in hypertrophic, dilated and ischemic cardiomyopathy together with its functional
consequences of conduction velocity slowing, dispersed impulse conduction, its interaction with ﬁbrosis and
propensity to generate arrhythmias. Finally, different therapies are discussed. Treatments aimed to improve
the Cx43 expression levels show new potentially anti-arrhythmic therapies during heart failure, but those in
the context of acute ischemia can be anti-arrhythmogenic at the cost of larger infarct sizes. This article is part
of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics.city; Cx43, connexin43; DCM,
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The electrical activation pattern of the heart normally starts in the
sinoatrial node (SAN) is then conducted along the atria, delayed in the
atrioventricular node (AVN), proceeds through the atrioventricular
conduction system and ﬁnally ends in the ventricles. Along this
pathway, all myocytes are individually activated by intercellular
currents that ﬂow through gap junctions.
In theheart, 3main gap junctionproteins are found in the conductive
andworkingmyocardial cells: Connexin40 (Cx40), Connexin43 (Cx43),
and Connexin45 (Cx45) (Fig. 1). Cx40 is expressed in atrialmyocytes, in
the AVN, His-bundle and ventricular conduction system [1–6]. Cx43 is
by far the most abundant, and is extensively expressed between atrial
and ventricularmyocytes and to lower degree in parts of the ventricular
conduction system [3,5,7–14]. Theexpression of Cx45 is restricted to the
SAN, the AVN, His-bundle and ventricular conduction system [5,15–18].
Normally, gap junctions (Cx43) between ventricular myocytes are
expressed in a polarized way. Gap junctions are mainly localized at
intercalated disks (IDs) at the cell poles, and have relatively low density
at lateral sides [12,13,19–22]. As a consequence, electrical conductioncan propagate in both longitudinal and transverse directions. This
conduction velocity (CV) is normally higher in the longitudinal than in
the transverse direction, giving rise to the phenomenon of anisotropy
[23,24].
Changes in cardiac workload, either by extrinsic factors, such as
pressure or volume overload, or by intrinsic factors such as myocardial
infarction or familial hypertrophic cardiomyopathy, generally induce
hypertrophic growth of individual myocytes. The classic view is that
hypertrophic growth of myocytes counteracts the increased wall
tension (Laplace's law), and is therefore often called compensated
hypertrophy [25,26]. Although called compensatory, a prolonged state
of hypertrophy increases the risk for progression into heart failure
(decompensated hypertrophy). Heart failure has a high morbidity and
mortality, which is strongly determined by the high propensity of
remodeled hearts to fatal ventricular tachyarrhythmias [27–33].
The cardiac remodeling process is governed by structural and
electrical changes that decrease the electrical stability of the heart.
A hallmark of the electrical changes with regard to impulse conduc-
tion is a change in electrical coupling due to abnormal expression of
Cx43-constituted gap junctions. Cx43 protein expression is typically
down-regulated and channels are often heterogeneously redistrib-
uted. This abnormal Cx43 expression is often associated with ab-
normal conduction and arrhythmias, although there seems to be a
large reserve before reduced intercellular coupling becomes arrhyth-
mogenic [34–36].
In previous reviews we focused on the structure, properties and
knockout animal models of Cx43, while in the current review we will
focus on Cx43 remodeling in hypertrophic, dilated and ischemic cardio-
myopathies and their functional consequences, both in human and
animal studies (Table 1) [37–39].
Cx45 Cx43Cx40
Fig. 1. Summary expression patterns of Cx40, Cx43 and Cx45 in the mammalian heart
(redrawn after [132]).
2021M.S.C. Fontes et al. / Biochimica et Biophysica Acta 1818 (2012) 2020–20292. Electrical coupling, impulse conduction and arrhythmias
Electrical coupling is essential for normal impulse propagation
through theheart, togetherwithproperexcitabilityof the cardiomyocytes
and normal tissue architecture. Reduced electrical coupling can increase
the propensity for arrhythmias by facilitating reentry activity. ‘Circulating
excitation’wasﬁrst recognized byGeorgeMines as a possiblemechanism
of arrhythmias [40] and he already showed that: ‘The circumstances
under which the phenomenon made its appearance were such as to
produce the favourable conditions of slow conduction and short
refractory period’. The relation between CV, the effective refractory
period (ERP) and reentrywas later captured in the term ‘wavelength’ (λ)
which is the distance of the impulse traveled during the refractory period
(λ=CV×ERP [41]). Usually,λ is too large to facilitate reentry. In amouse
heart, e.g., CV is ~40 cm/s and ERP is ~50 ms [42], resulting in a λ of 2 cm,
which is too large to ﬁt on a mouse heart. Conditions that shorten the
refractory period or decrease CV will result in a shorter λ, which may ﬁt
more easily on the heart, thus increasing the propensity for reentrant
arrhythmias. Conversely, conditions that prolong refractoriness or
increase CV are expected to prolong the wavelength and reduce
arrhythmogeneity [41,43].
Reduced expression of Cx43, leading to reduced intercellular
coupling is usually associated with reduced CV. However, the
relationship between electrical coupling and CV is not linear [44],
and solid reductions in Cx43 expression are required for reduction of
CV. Mice heterozygously deﬁcient for Cx43 showed 50% reduction in
Cx43 expression that was associated in some studies with reduced CV,
but in others with no effect in the CV [42,45–49]. Reduction of about
90% in Cx43 expression resulted in about 50% decrease in the CV
[42,50]. While 50% reduction in Cx43 may lead to some conduction
slowing, high levels of electrical uncoupling are needed to increase
arrhythmogeneity. Abnormal tissue architecture, e.g. due to increase
of collagen deposition (ﬁbrosis), may have synergistic effects together
with reduced Cx43 expression and lead to conduction slowing as
reviewed by [51].3. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is categorized as concentric
hypertrophy, with thickening of the left ventricular (LV) wall without a
signiﬁcant dilation of the LV cavity, and is also characterized by
cardiomyocyte hypertrophy, myoﬁbrillar disarray, and ﬁbrosis (Fig. 2)
[27,52]. HCM is usually associated with pressure overload due to aortic
stenosis or chronic hypertension [27].
In LVbiopsies ofHCMpatientswith valvular aortic stenosis, Cx43was
subject to a remodeling process between compensated and decom-
pensated hypertrophy. As mentioned above, compensated hypertrophy
reﬂects properworkingmyocardium(e.g. ejection fractionN50%),which
mayprogress to a failingmyocardium,decompensatedhypertrophy(e.g.
ejection fractionb30%).While compensated hypertrophy had increased
levels and increased lateral Cx43 expression, decompensated hypertro-
phy revealed a heterogeneous reduction of Cx43 [53]. In other human
studies, besides myoﬁber disarray, a Cx43 redistribution from IDs to thelateral sides of cardiomyocytes, resulting in reduced Cx43 at the IDs, was
reported [21,54,55]. The reduction of Cx43 was not associated with a
change in the number of IDs, although they presented an abnormal
organization as well as abnormal desmosome organization [55]. In
contrast with the above observation of a Cx43 down-regulation, an
increase of Cx43 expression levels in LV biopsies fromHCMpatients was
recently reported for the ﬁrst time [54].
Some animal models of HCM showed changes in Cx43 expression
similar to that found in humans. A study of transgenic rabbits bearing
a mutation in Troponin I that causes HCM in humans, revealed typical
HCM characteristics such as cardiomyocyte disarray, ﬁbrosis, and
Cx43 disorganization. This disorganization was reﬂected by a
heterogeneous redistribution of Cx43 together with increased levels
and increased phosphorylation of Cx43. In these transgenic rabbits no
ECG abnormalities were detected, except an altered repolarization
phase. The heterogeneous expression of Cx43 did not lead to
enhanced arrhythmogeneity, perhaps due to the overall increased
levels of Cx43 [56]. Cx43 up-regulation was also detected in another
rabbit model of HCM (β-myosin heavy chain-Q403), but only in the
midmyocardium. No effect on action potential duration, conduction
velocities and anisotropy was detected [57].
In a guinea pig model with chronic aortic stenosis a reduction in the
expression of Cx43, remodeling of IDs and alteration in myocyte shape
was observed after transition from compensated to decompensated LV
hypertrophy [58].
Finally, a rat model of HCM (monocrotaline-induced pulmonary
hypertension or pressure overload) showed, in both right and left
ventricle, a normal distribution of desmoplakin in the IDs and normal
levels of total Cx43, although there was redistribution of Cx43 from the
IDs to the cytoplasm and lateral sides of myocytes, and increased
dephosphorylated Cx43 [59–61]. Furthermore, measurements of CV in
the right ventricle revealedadecrease in the longitudinaldirectionwhen
compared with control, while transversal CV remained unchanged,
resulting in reduced anisotropic ratio [59]. Reduced longitudinal CV
probably resulted from reduced Cx43 at IDs, while unchanged
transversal CV probably resulted from non-functional lateral Cx43,
whichmay reﬂect the increase in dephosphorylation of Cx43. In another
ratmodel of pressure overload by ascending aortic banding, a reduction
in Cx43 expression, an increase in dephosphorylated Cx43 and a
reduction in CV in the late stage of hypertrophy was found [62].
However, as described above in a human HCM study, in early stages of
hypertrophy the typical increase of Cx43 was observed, but also an
increase in phosphorylation of Cx43, and slowing of CV that was less
severe than observed in the late stage. In this animal model of pressure
overload it was possible to induce sustained ventricular tachyarrhyth-
mia [62].
Reports from HCM patients and different animal models revealed
an increase and lateralization of Cx43 together with slowing of CV in
early, compensated stage of hypertrophy that was followed by a
reduction of Cx43, resulting in development of arrhythmias.
4. Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is characterized by eccentric hyper-
trophy, with thickening of the LVwall in conjunction with an increase in
the diameter of the LV cavity (Fig. 2). It is usually associatedwith volume
overload, as aortic or mitral valve regurgitation and anemia or as muscle
dysfunction [27,29,63].
Left ventricular biopsies from patients with DCM showed heteroge-
neous down-regulation of Cx43 expression,with a greater loss in the IDs
compared to the lateral sides [54,64,65]. In small areas of replacement
ﬁbrosis therewas a redistributionof Cx43,whereas in areas distant from
this region, Cx43 was normally distributed in the IDs [65]. Hearts from
DCM patients who died suddenly also showed reduction and redistri-
bution of Cx43 expression in both ventricles [66]. Since the control
hearts used in this study were from patients without DCM, no
Table 1
Abnormal Cx43 expression in heart remodeling.
Cardiomyopathy Origin Cx43 Fibrosis CV Arrhythmias Comments References
Expression Phosphorylation Distribution
Heterogeneous Lateralized
HCM Human ↑ ↑ Myoﬁber disarray, remodeling of IDs [21]
↑ LV (early stage)
↓ LV (late stage)
↑ LV ↑ LV (early stage) [53]
↓ LV [55]
↑ LV ↑ LV [54]
Rabbit ↑ ↑ ↑ ↑ = Cardiomyocyte disarray, altered repolarization phase [56]
↑ (Midmyocardial) = ↑ LV transmural ﬁber rotation, normal APD [133]
Guinea
Pig
↓ LV Altered ventricular myocyte shape, remodeling of
IDs
[58]
Rat ↓ RV (IDs) ↑ RV ↓ CVL
=CVT
[59]
↓ LV ↑ LV ↑ LV [60]
=RV ↓ RV ↑ RV [59–61]
↑ (early stage)
↓ (late stage)
↑ (early stage)
↓ (late stage)
↑ (late stage) ↓ (early stage)
↓↓ (late stage)
↑ ↑ APD [62]
DCM Human ↓ ↑ = ↑ [67,68]
↓ ↑ [66]
↓ LV ↑ LV [64]
↓ LV (distant from ﬁbrosis) ↑ LV (areas of ﬁbrosis) [65]
↓ LV ↑ LV [54]
Pig ↑ (early stage)
↓ (late stage)
↑ (late stage) Expansion of cardiomyocytes myoﬁlaments [80]
Dog ↓ LV ↓ ↑ LV ↑ LV = ↓ ↑ ↑ QRS interval
No change in action potential upstroke velocity
[69]
↓ ↓ ↑ ↓ [75]
Rabbit ↑ [81]
Mouse ↓ ↑ ↑ LV ↓
Heterogeneous
= ↑ QRS interval
Regional conduction block
[77]
↓ ↓ [78]
= ↑ (VT+) ↑ ↓ RV CVL
Heterogeneous
↑
(44%)
↓ Fractional shortening
↑ PQ, QT and QRS prolongation
[79]
ICM Human ↓ (distant from BZ) ↑ (BZ)
= (distant from BZ)
↑ (BZ) Altered myocyte orientation and cell shape in BZ [85,134]
= CVL
↓ CVT
↑ Refractory period [86]
↓ LV = LV Change in cell size distribution [55]
↓ LV ↑ LV ↑ Cx40 [64]
↓ (distant from BZ) ↑ (BZ)
= (distant from BZ)
[65]
Dog ↓ ↑ (BZ) Cardiomyocyte disarray [96]
↓ ↓ ↑ [87]
= CVL
↓ CVT
↑ [100]
↑ ↑ ↑ (BZ) ↑ [101]
Pig ↓
Heterogeneous
[104]
Rabbit ↓ ↑ [88]
↓ [89]
Rat = ↓ [90]
↓ ↑ [105]
↓ ↑ [106]
Abbreviations: HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; ↑, increased; ↓, decreased; ↓↓, more decreased than ↓; =, unchanged; LV, left ventricle; RV, right ventricle; CVL, longitudinal
conduction velocity; CVT, transversal conduction velocity; VT+, occurrence of ventricular tachycardia; BZ, border zone; ID, intercalated disk; APD, action potential duration.
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Fig. 2.Morphologic differences between normal and cardiomyopathic hearts. From left to right: normal, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and
ischemic cardiomyopathy (ICM). In ICM a border zone (BZ) is present between the infarct zone (IZ) and the normal zone (NZ).
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cardiac death in DCMpatients. In order to ﬁndmore about the substrate
of arrhythmias, DCM patients were subdivided in patients with
ventricular tachycardia (VT+) or without VT (VT−) and in patients
with late ventricular potentials (LP+) or without LP (LP−). Left
ventricular ejection fraction was similar in VT and LP groups and the
amount of ﬁbrosis was not measured in VT groups but it was similar in
LP groups. VT+and LP+patients showed a reduced and heterogeneous
distribution of Cx43 when compared with VT− and LP−, and LP+
patients presented high susceptibility for ventricular tachycardia
[67,68]. This suggests that heterogeneous reduction of Cx43, which is
relatedwith the presence of ventricular tachycardia and late ventricular
potentials,may play a role in development of ventricular arrhythmias in
DCM patients, possibly reﬂecting the patient's arrhythmic risk.
Several animal models of DCM showed similar reductions in Cx43
expression. In a canine pacing-tachycardiamodel of DCM, epicardial and
endocardial CVs in both ventricles were decreased by more than 20%
[69]. In the epicardial and endocardial LV, Cx43 expression levels were
decreased by 40% with Cx43 beingmore expressed in epicardial than in
the endocardial tissue. Contrarily, epicardial CV was further decreased
when compared with endocardial CV. In both ventricles, there was
lateralization and dephosphorylation of Cx43 as well as prolongation of
theQRS interval although no changewas detected in the action potential
upstroke velocity or in ﬁbrosis. The propensity for induced polymorphic
ventricular tachycardia was increased in this model and associated with
decreasedwavelength [69]. In this study, thedecreased epicardial CVdid
not seem to correlate with the increased epicardial Cx43 expression
(when compared with endocardial Cx43 expression) or with reduced
excitability because the action potential upstroke velocity was
unchanged. The prolongation of the QRS interval can result from the
remodeling of potassium currents in the failing heart like the reduction
in the inward rectiﬁer K+ current, but also from the down-regulation in
the peak of the Ca2+-independent transient outward current, although
Na+ current remained unchanged [70,71]. In addition,QRS prolongation
might be due to enlargement of the heart without any effect on the
absolute value of CV [72]. Interestingly, another study on the same
preparation has shown that Cx43 heterogeneity also leads to transmural
heterogeneity of action potential duration,whichmay also be part of the
arrhythmogenic substrate [73,74]. In thementioned caninemodel it was
demonstrated that the reduction of Cx43 precedes the slowing of CV,
perhaps because reduction of Cx43 alone is not sufﬁcient for conduction
slowing [42,49,75]. The development of ﬁbrosis, in conjunction with
reduced Cx43may be needed for conduction slowing [76]. The increase
in dephosphorylation of Cx43 was associated with later stages of heart
failurewhile Cx43 lateralization appears in an even later stage, when the
CV is signiﬁcantly reduced [75].
A mouse model of DCM induced by forced retinoic acid signaling
revealed a prolongation of the QRS interval, decreased conduction
velocity, increased conduction heterogeneity, regional conduction block
but these mice were not susceptible to ventricular arrhythmias. A
reduction of Cx43was accompanied by Cx43 lateralization in the border
zones of the affected intramural area in the LV free wall [77,78]. Theheterogeneous reduction of Cx43 may play a role in the appearance of
the regional conduction block. The reduction in Cx43 presumably was
followed by a reduction in other intercellular junction proteins, β-
catenin andN-cadherin.Besides, therewasheterogeneous re-expression
of the hypertrophic markers like α-skeletal actin and β-MHC and in
someseverely affectedmice low levels of Cx40 re-expressionwere found
[77]. Since Cx40 expression levels were low, compensation by this
connexin isoform can presumably be excluded. A murine model of
longstanding pressure overload subjected to transverse aortic constric-
tion (TAC) showed an increase in LV end-diastolic and end-systolic
volumes, a decrease in fractional shortening, and a rapid structural and
electrical remodeling. Electrical remodeling was reﬂected by gradual
decrease in PQ,QT andQRSprolongation and by reduced longitudinal CV
in the right ventricle. Structural remodeling was reﬂected by heteroge-
neous expression of Cx43 and increased interstitial ﬁbrosis in TAC mice
while Cx43 expression levelswere similar to control hearts. In this study
44% of the TACmicewere susceptible to induce polymorphic ventricular
tachycardia. The only difference found in TAC mice with and without
arrhythmias was a more pronounced heterogeneity of Cx43 expression
in the arrhythmogenic TACmice [79]. Thus, the arrhythmias found in this
animal model of pressure overload seemed to be associated with
heterogeneous expression of Cx43, which may lead to functional
block and unstable reentry, resulting in polymorphic ventricular
tachyarrhythmias.
Interestingly, in a pigmodel of DCM, expression of Cx43was increased
in the early stage of hypertrophy, but with its progression into heart
failure, the levels of Cx43 decreased, cardiomyocytes myoﬁlaments
expanded and ﬁbrosis increased [80]. Up-regulation of Cx43 in acute
stages of hypertrophy in DCM but also in HCM may represent an
immediate compensatory response of the heart to increased workload. A
rabbit model of DCM due to surgically aortic regurgitation showed an
increase in expression of Cx43 over time comparedwith control hearts in
which expressionof Cx43 remained similar up to 2.5 years [81]. This is the
opposite towhatwas found inother animalmodels ofDCMinwhichCx43
expressiondecreasedover time.Theoverall up-regulationofCx43 in these
previous studies could also result from beta-adrenergic stimulation. After
24 h of beta-adrenergic stimulation, an increase in Cx43 expression was
observed in culturedneonatal rat cardiomyocytes, aswell as an increase in
gap junction currents [82]. However, in a different study on the same
preparation, 24 h of beta-adrenergic stimulation lead to an increase in CV
but had no effect on expression or distribution of Cx43, other than a slight
increase in phosphorylated Cx43 [83].
In DCM, heterogeneous reduction of Cx43 seems to be closely
related with the presence of ventricular tachycardia in both patient
and animal models, perhaps because the concomitant development of
ﬁbrosis is prerequisite for CV slowing. Besides that, prolongation of
the QRS interval is possibly related with disturbances in ion channels.
5. Ischemic cardiomyopathy
Ischemic cardiomyopathy (ICM)usually results fromcoronaryartery
disease and can be divided in an acute phase followed by a chronic
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with reduced intercellular coupling. The chronic phase refers to
healing/healed infarcts that correspond to the tissue that is recovering
from the suffered ischemia and since it is a late stage, is associated with
changes in the Cx43-constituent gap junction expression and/or
trafﬁcking. After acute myocardial infarction, there is the formation of
a compact infarct scar surrounded by a border zone (BZ) that separates
the infarct scar fromnormal tissue (Fig. 2) [27,29]. TheBZ is composedof
damaged but still viable muscle ﬁbers, with abnormal physiological
properties [84].
Thepresenceofmyocytebridges extendedacross infarctedareas and
coupled by gap junctions, suggests the existence of impulse propagation
between areas of healthy myocardium, although in some cases those
bridges weremade up from a single myocyte [85]. Impulse propagation
in these conditions caused transversal CV slowing due to a “zigzag”
course of activation performed by impulses between healthy myocar-
dium, although the longitudinal CV remained unchanged [86].5.1. Acute myocardial infarction and changes in gap junction function
In a canine model of infarction, active membrane properties were
largely affected in acute ischemia, followed by a partial recovery of the
surviving myocytes, with the action potential duration remaining
reduced [84]. One hour after ischemia, Cx43 was dephosphorylated
and heterogeneously reduced in infarcted areas, and after acute
ischemia small amounts of Cx43 were detected at the lateral sides of
cardiomyocytes, although the signal at IDs was practically gone [87]. In
an isolated perfused rabbit heart model of ischemia/reperfusion, the
reduction of Cx43 over time is in accordance with that described in the
canine model. Besides a redistribution of Cx43, another intercellular
junction protein N-cadherin was reduced and structure integrity was
altered. Despite these disturbances, epicardial CV anisotropy was
unchanged [88]. In arterially blood-perfused rabbit papillary muscles
there was an increased extracellular longitudinal resistance during the
acute, reversible phase of myocardial ischemia, while intracellular
longitudinal resistance remained unchanged, resulting in unaffected
electrical coupling. During this phase, the increased extracellular
resistance most likely contributed to the small slowing of CV observed.
On the other hand, after 15–20 min of ischemia, increased intracellular
longitudinal resistance resulted in rapid electrical uncoupling. This
probably leads to CV slowing that may be an important factor for the
occurrence of arrhythmias during this phase of ischemia [89]. In an
isolated perfused adult rat heart model of ischemia/reperfusion a
progressive dephosphorylation of Cx43 over time during ischemia was
observed together with progressive electrical uncoupling and progres-
sive reduction in total Cx43 immunoﬂuorescent signal, while in control
hearts practically all Cx43 remained phosphorylated. Although the total
amount of Cx43 did not change, the decrease in total Cx43 immuno-
ﬂuorescent signal and increase in dephosphorylated Cx43 at IDs were
probably related with the electrical uncoupling. After reperfusion, the
functional recovery was associated with an increase in the phosphor-
ylation of Cx43. These observations lead the authors to suggest that
uncoupling induced by ischemia was also associated with a transloca-
tion of Cx43 from gap junctions to intracellular sites, although this was
not demonstrated [90]. In neonatal rat ventricular myocyte monolayers
with induced acute regional ischemia/reperfusion, a slower CV was
observed after a slow recovery from Cx43 dephosphorylation during
early reperfusion [91]. This slow recovery fromCx43dephosphorylation
may be a fundamental factor for the creation of a highly arrhythmogenic
substrate by prolonging slow conduction after recovery of the
membrane excitability. Different studies indicated the following serine
positions of Cx43, Ser297/368, Ser325/328/330 or Ser365, as being
phosphorylated in normal conditions and dephosphorylated during
ischemia [92–94]. However, the functional consequences of (de)
phosphorylation at these different sites are not known, nor the relationof dephosphorylated Cx43 with the redistribution of Cx43 from IDs to
the lateral sides of myocytes.
5.2. Chronic myocardial infarction and gap junction remodeling
Areas of the BZ in human healed infarcts revealed alterations in
myocyte orientation and in cell shapewithmore rounded or attenuated
forms being present, enlargement ormultiple nuclei, and disorientation
of the individual myoﬁlaments in the intact myoﬁbrils [85]. Contrarily,
areas of myocardium distant from the healed infarct appeared to be
well-preserved with arrangement of ﬁbers, IDs and an overall cellular
structure resembling that of normalmyocardium [85,95]. In areas of the
BZ of healed infarcts a heterogeneous redistribution of Cx43 to the
lateral sides of myocytes was detected in contrast with areas distant
from healed infarcts, where the number of IDs remained the same as in
control heart and Cx43 was conﬁned to well-deﬁned IDs
[55,64,65,85,95]. Although these regions distant from the infarct scars
(called normal zone) revealed normal Cx43 distribution, the amount of
Cx43 was reduced and the cell size distribution was changed
[55,64,65,95]. Up-regulation of Cx40 detected in the endocardium
may represent a compensatory response to the decrease in Cx43 [64].
The BZ of infarcted canine hearts was characterized by reduced and
altered kinetics of sodium current, slower CV and down-regulation of
Cx43, with lateral Cx43 being more reduced than in IDs [84,88,96,97].
These observations suggest an increased axial resistivity in the transverse
direction, possibly contributing thisway to the development of reentrant
arrhythmias [96]. Cx43 remodeling that resulted in a relative myocyte
uncoupling was described together with an increase in interstitial
ﬁbrosis, distortedmuscle ﬁbers andmyocyte disarray, pointing to a non-
uniform anisotropic structure [84,96,98]. Concerning the electrical
remodeling, another canine model of infarction presented a reduction
in transverse coupling conductance [99] which is in accordance with
decreased transverse CV [100], while longitudinal coupling and CV
remained unchanged. Surprisingly, no reduction in Cx43 expression was
detected, suggesting the presence of non-functional gap junctions, an
increase in gap junction proteins dephosphorylation, or changes in other
ion channels which e.g. alter the passive membrane properties [99]. The
decrease in transverse conductance andCV (longitudinally oriented lines
of apparent block) most probably contributed to the occurrence of
reentry in this model of infarction and this is a key factor in the
development of ventricular tachycardia [100]. Moreover, the abnormal
redistribution and lateralization of Cx43 observed in the epicardical BZ
occurred before the presence of increased ﬁbrosis indicating an early
post-infarction remodeling. This disturbance in Cx43 distribution was
associated with the location of the central common pathways of the
ﬁgure-of-8 reentry [101]. Cabo and coworkers [102] described some
differences between the central common pathway (CCP) and outer
pathway (OP) of the reentrant circuit in the canine epicardial BZ. The CV
in OPmyocytes was reducedwith transversal CVmore reduced than the
longitudinal one, leading to an increase in the anisotropic ratio. In these
cells the transversal gap junctional conductance decreased while the
longitudinal conductance remained normal when compared to control
tissue. In OP myocytes there was no Cx43 lateralization. Instead, in CCP
myocytes a lateralization of Cx43was observed. In these cells, transversal
and longitudinal gap junctional conductances were similar to that of
normal tissue as well as the anisotropic ratio, which reﬂects the equal
reduction in transversal and longitudinal CVs. The decrease in longitu-
dinal CVwas bigger in CCP than inOPmyocytes [102]. These changes can
result from the heterogeneous remodeling of ion channels in the
epicardial BZ. A previous study from the same group showed a reduction
in sodium and calcium current densities in CCP and OP myocytes [103].
Thus, a combined effect of altered Cx43 and ion channel expressionmay
explain the differences in the observed CVs. In the acute and reversible
phase of myocardial ischemia in isolated porcine hearts, there was also a
heterogeneous reduction in longitudinal and transversal CVanda shorter
amplitudeof the actionpotentials,which seemtobe initiatedby the rapid
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Cx43 was observed in well-deﬁned IDs [105]. In acute ischemia Cx43,
desmoplakin and cadherin expressions in the BZ of the infarct were
reduced and redistributed to the lateral borders of cardiomyocytes,
which further deteriorated during the chronic phase [105,106]. The IDs
were remodeled, changing its form into tentacle-like structures in the BZ
of the infarct, which was followed by the temporally presence of small
amounts of Cx43 expression at the lateral sides of cardiomyocytes and by
the increased deposition of extracellular matrix proteins like β1-integrin
[105,106]. These changes may contribute to alterations of the CVs in the
BZs of the infarct.
In ICM practically all the animal models presented a heterogeneous
redistribution and reduction of Cx43 in the BZ of the infarcts, usually
followed by slowing of CV either in the longitudinal or transverse
direction, and by an ongoing increase in ﬁbrosis. In the caninemodel of
infarction the occurrence of reentrant arrhythmias and a decrease in the
sodium current was also reported.
6. Therapies
As described above, expression of Cx43 in the heart is strongly
remodeled in different forms of cardiomyopathy. Therefore, several
attempts have been made to improve electrical coupling and, as a ﬁnal
goal, to reduce arrhythmogenesis which is frequently present in these
diseases.
Some of the treatments already used in rat, rabbit, guinea pig or
canine models of different cardiomyopathies are: rotigaptide, which
increases gap junction intercellular communication; diltiazem, an L-type
calcium channel blocker; estrogen; sotalol, a potassium channel blocker;
omega-3 fatty acids, unsaturated fatty acids; atorvastatin, a member of
statin class of drugs; gap26, a synthetic structural mimetic peptide
deriving from the ﬁrst extracellular loop of Cx43; losartan, which is an
antagonist of angiotensin II type 1 receptor; apocynin, which is an
inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase, a major source of reactive oxygen species in the heart; and
targeted external heavy ion beam irradiation (THIR) (Table 2).
Losartan reduced LV hypertrophy and Cx43 disorganization, as Cx43
remained mainly at IDs [60]. Inhibition of the renin–angiotensin–
aldosterone system in other studies also resulted in prevention of gap
junction remodeling, suppression of ﬁbrosis, normalization of impulse
conduction, and increased electrical stability [107,108]. THIR increased
LV lateralization and expression of Cx43, which in normal heart lasted
up to one year after a single THIR treatment and improved conductivity,
decreased spatial heterogeneity of repolarization, and reduced the
vulnerability for ventricular arrhythmias after myocardial infarction
[109,110]. Estrogen reduced Cx43 dephosphorylation, myocyte apo-
ptosis and infarct size, and reduced the vulnerability to ventricular
arrhythmias [111–113]. Diltiazem improved LV function and reduced
Cx43 dephosphorylation after reperfusion [114]. Apocynin reduced the
vulnerability for ventricular arrhythmias, increased Cx43 expression
and phosphorylation, decreased interstitial ﬁbrosis and increased
SERCA2a expression and activity [115,116]. The improvement in cardiac
dysfunction was also characterized by shortening of QRS interval, ERP
and monophasic action potential duration at 90% repolarization [115].
Sotalol prevented ischemia-induced electrical uncoupling although
there was still shortening of the action potential duration and also
improved electrical coupling after acute ischemia [117]. In another
study sotalol increased CV and the ERP, and the propensity for induced
ventricular tachycardia was markedly decreased [118]. Omega-3 fatty
acids and atorvastatin increased Cx43 expression although there was a
decrease in the phosphorylation of Cx43, preserved the integrity of
cardiomyocytes and gap junctions, and decreased the propensity for
induced ventricular ﬁbrillation, although ﬁbrosis was not reduced
[119,120]. Gap26 protected the heart against ischemic injury by
reducing the infarct size by half, either when applied before or during
ischemia [121]. Rotigaptide reduced the infarct size, enhanced gapjunctional conductance and suppressed reentrant ventricular tachycar-
dia during ischemia, although no effect was observed in ERP, surface
ECG parameters and blood pressure [122,123]. In epicardial BZ,
rotigaptide increased Cx43 but had no effect on Cx43 phosphorylation
or lateralization. However, rotigaptide in the epicardial BZ did not
suppress ventricular tachycardia and did not improve CV, although the
ERP was decreased [124]. Since Cx43 in epicardial BZ was not totally
recovered, this could reﬂect the non-improvement of CV and in
prevention of arrhythmias. In explanted perfused hearts from patients
with end-stage heart failure, rotigaptide resulted in decreased ERP,
increased longitudinal CV and normalized longitudinal conduction
curves, althoughwith destabilized transversal conduction curves [125].
Although most of the studies associate the improvement of electrical
coupling as being anti-arrhythmogenic, some studies demonstrate
the opposite after coronary occlusion: mice with 50% reduction of Cx43
presented an infarct size smaller than in normal mice [126]; mice with a
deletion of the carboxyl terminal domain of Cx43 showed an increase
in the infarct size [127]; and mice expressing Cx32, which is a
connexin isoform pH- and voltage-independent, presented an increase
in infarct size compared with control mice [128,129]. The effect on
arrhythmogeneity was found to be beneﬁcial [129] or absent [128].
Therefore, improving intercellular coupling during acute ischemia can
have anti-arrhythmic effects, but will also lead to increased infarct size
after coronary occlusion.
These ﬁndings suggest that strategies that suppress Cx43 remo-
deling can be potential new anti-arrhythmic targets, especially in the
context of heart failure associated arrhythmias. The opportunities for
treatment of ischemia related arrhythmias are more limited, because
reduction of arrhythmogeneity is achieved at the cost of increased
infarct size.7. Conclusions
Abnormal Cx43 expression in the heart has been reported in
several forms of cardiomyopathies as hypertrophic, dilated and
ischemic cardiomyopathy. Generally, Cx43 is down-regulated and
heterogeneously redistributed throughout the heart, and in some
cases it is lateralized. This abnormal Cx43 expression is often followed
by a reduction in the CV, which then seems to be accompanied by an
increase in ﬁbrosis. All these disturbances may lead somehow to the
development of arrhythmias (Fig. 3). In addition, ventricular
tachycardia seems to be associated with the heterogeneous reduction
of Cx43. One of the explanations for conduction slowing is the Cx43
redistribution and the decrease in the phosphorylation of Cx43, but
other factors can also be involved like altered repolarization phase
and a reduction in the sodium current. An interesting factor in the
ischemic heart is the up-regulation of Cx43 in ﬁbroblasts [130], that
can also play a role in the disturbance of the CVs. Prolongation of the
QRS interval can possibly be related with disturbances in ion channels
and prolongation of the action potential duration can possibly be
related with the decrease in the intercellular coupling conductance
[131]. In addition to the general down-regulation of Cx43, in some
cases Cx43 is up-regulated in early, compensated stage of hypertro-
phy but followed by a down-regulation, which could reﬂect a
compensatory mechanism to the workload.
Several approaches that successively improved Cx43 expression
levels or Cx43 conductance and reduced thevulnerability for ventricular
arrhythmias open the opportunity for potentially new anti-arrhythmic
therapies for heart failure.
In conclusion, the functional consequences of reduced and hetero-
geneous Cx43 expression in the heart are slow and dispersed impulse
conduction, which may increase the propensity to generate arrhyth-
mias, especially when combined with increased ﬁbrosis. Treatments
aimed to improve theCx43expression levels shownewpotentially anti-
arrhythmic therapies during heart failure, but those in the context of
Table 2
Therapy treatments to reverse the abnormal Cx43 expression in heart remodeling.
Therapy Tissue origin Cx43 Fibrosis CV Arrhythmias Comments References
Expression Phosphorylation Distribution
Heterogeneous Lateralized
Losartan Rat ↓ ↓ ↓ LV hypertrophy [60]
THIR Rabbit ↑ ↑ ↑ ↓ ↓ Spatial heterogeneity of repolarization [109]
Estrogen Rat ↑ ↓ ↓ Myocyte apoptosis [111]
↑ ↓ Infarct size, ↓ free radicals [113]
↑ ↓ ↓ [112]
Diltiazem Rat ↑ ↑ LV function [114]
Apocynin Rabbit ↑ ↑ ↓ ↓ ↑ SERCA2a expression and activity, ↓ QRS interval, ↓ ERP, ↓MAP duration at 90%
repolarization
[115,116]
Sotalol Guinea Pig Recovery of electrical coupling, ↓ APD [117]
Rabbit ↑ ↓ ↑ ERP [118]
Omega-3 fatty
acids
Rat ↑ = ↓ = Hypertrophy [119]
↓ ↓ ↓ Preservation of cardiomyocytes and gap junctions integrity [120]
Atorvastatin Rat ↓ ↓ ↓ Preservation of cardiomyocytes and gap junctions integrity [120]
Gap26 Rat ↓ Infarct size [121]
Rotigaptide Canine ↓ ↑ Conductance
= ERP, surface ECG, mean arterial pressure or infarct size
[122]
↑ (gap junctions in
general)
↓ ↓ Infarct size
= Surface ECG, blood pressure
[123]
↑ (EBZ) = (EBZ) = (EBZ) =
(EBZ)
= (EBZ) ↓ ERP [135]
Human (ex-
vivo)
↑ CVL ↓ ERP
Destabilized transversal conduction curves
[136]
Abbreviations: THIR, targeted external heavy ion beam irradiation; ↑, increased; ↓, decreased;=, no effect; LV, left ventricle; CVL, longitudinal conduction velocity; EBZ, epicardial border zone; ERP, effective refractory period; MAP, monophasic
action potential; APD, action potential duration; ECG, electrocardiography.
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Fig. 3. Functional consequences of abnormal Cx43 expression after heart remodeling.
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